Nullscript inhibits Cryptosporidium and Toxoplasma growth

Area of Science:

• Parasitology
• Drug Discovery
• Immunology

Background:

• Cryptosporidium and Toxoplasma infections pose significant global health challenges, particularly for immunocompromised individuals.
• Current treatments like nitazoxanide have limited efficacy and poor patient tolerance.
• There is an urgent need for novel therapeutic agents against these opportunistic parasitic infections.

Purpose of the Study:

• To screen epigenetic compounds for inhibitory activity against Cryptosporidium parvum and Toxoplasma gondii.
• To identify novel drug candidates with improved efficacy and safety profiles.
• To evaluate the therapeutic potential of identified compounds in preclinical models.

Main Methods:

• Screening of epigenetic compound libraries against C. parvum growth.
• In vitro assessment of compound efficacy and host cell toxicity.
• In vivo evaluation of lead compounds in a Cryptosporidium-infected SCID mouse model.

Main Results:

• Nullscript was identified as a potent inhibitor of both C. parvum and T. gondii growth.
• Nullscript demonstrated reduced toxicity to host cells compared to existing treatments.
• Administration of Nullscript significantly reduced oocyst excretion in C. parvum-infected mice.

Conclusions:

• Nullscript represents a promising novel therapeutic candidate for cryptosporidiosis and toxoplasmosis.
• The compound's dual activity against both parasites warrants further investigation.
• Nullscript's favorable safety and efficacy profile suggests potential clinical utility, especially in immunocompromised populations.